You are here

Ossur Hf : Transactions in relation to share buyback program

Announcement no. 64/2018

29 October 2018

Transactions in relation to share buyback program

On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018.

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 30 June 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions have been made under the program in week 03, the period 22 October 2018 - 26 October 2018:

Transactions

Date

No. of shares

Avg. purchase price in DKK

Transaction value in DKK

22 October 2018

1,291

32.38

41,808

23 October 2018

4,780

32.38

154,764

24 October 2018

5,000

32.33

161,671

25 October 2018

25,000

32.10

802,418

26 October 2018

24,681

31.99

789,553

Total

60,751

32.10

1,950,214

Össur has acquired 229,961 shares under the program at the average price of DKK 30.92. Following the above transactions Össur's holding of own shares is 6,358,654 corresponding to 1.48% of the Company's total share capital.

The share buyback program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.

Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports. A recognized "Technology Pioneer," Össur invests significantly in research and product development-its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com